EGFR and cancer: This study was designed with the hypothesis that mebendazole (MBZ) and gefitinib (GEF) act synergistically by simultaneously disrupting cytoskeletal integrity and epidermal growth factor receptor (EGFR)-mediated signaling, thereby impairing paracrine cytokine communication and reducing survival in aggressive cancers.